XOMA Royalty Valuation

Is 0M26 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0M26 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0M26's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0M26's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0M26?

Key metric: As 0M26 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0M26. This is calculated by dividing 0M26's market cap by their current revenue.
What is 0M26's PS Ratio?
PS Ratio	16.9x
Sales	US$21.61m
Market Cap	US$365.38m

0M26 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	15.8x
Enterprise Value/EBITDA	-22.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0M26's PS Ratio compare to its peers?

The above table shows the PS ratio for 0M26 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10.9x
OXB Oxford Biomedica	4.6x	21.0%	UK£447.8m
BVXP Bioventix	14.4x	n/a	UK£195.7m
GNS Genus	1.7x	3.5%	UK£1.1b
OPTI OptiBiotix Health	22.8x	n/a	UK£13.0m
0M26 XOMA Royalty	16.9x	31.3%	US$365.4m

Price-To-Sales vs Peers: 0M26 is expensive based on its Price-To-Sales Ratio (16.9x) compared to the peer average (10.9x).

Price to Sales Ratio vs Industry

How does 0M26's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.6x	21.0%	US$561.69m
TRX Tissue Regenix Group	1.6x	15.1%	US$50.93m
VRCI Verici Dx	2.4x	78.8%	US$10.27m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0M26 is expensive based on its Price-To-Sales Ratio (16.9x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0M26's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0M26 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	16.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0M26's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0M26 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$31.00	US$86.00 +177.4%	36.0%	US$117.00	US$55.00	n/a	2
Nov ’25	US$30.04	US$83.00 +176.3%	41.0%	US$117.00	US$49.00	n/a	2
Oct ’25	US$27.01	US$83.00 +207.4%	41.0%	US$117.00	US$49.00	n/a	2
Sep ’25	n/a	US$83.00 0%	41.0%	US$117.00	US$49.00	n/a	2
Aug ’25	US$27.00	US$58.00 +114.8%	27.6%	US$74.00	US$42.00	n/a	2
Jul ’25	n/a	US$58.00 0%	27.6%	US$74.00	US$42.00	n/a	2
Jun ’25	n/a	US$58.00 0%	27.6%	US$74.00	US$42.00	n/a	2
May ’25	US$25.44	US$57.00 +124.1%	29.8%	US$74.00	US$40.00	n/a	2
Feb ’24	US$21.04	US$62.50 +197.1%	10.4%	US$69.00	US$56.00	n/a	2
Jan ’24	n/a	US$62.50 0%	10.4%	US$69.00	US$56.00	n/a	2
Dec ’23	US$21.55	US$62.50 +190.0%	10.4%	US$69.00	US$56.00	n/a	2
Nov ’23	n/a	US$62.50 0%	10.4%	US$69.00	US$56.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.80

1.9%

12.1%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

-16.8%

2.1%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

0.5%

-5.7%